Share-based Payment Arrangement, Expense of NewAmsterdam Pharma Co N.V. from 31 Dec 2021 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NewAmsterdam Pharma Co N.V. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
  • NewAmsterdam Pharma Co N.V. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $14,023,000, a 49% increase year-over-year.
  • NewAmsterdam Pharma Co N.V. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $59,425,000, a 77% increase year-over-year.
  • NewAmsterdam Pharma Co N.V. annual Share-based Payment Arrangement, Expense for 2025 was $59,425,000, a 77% increase from 2024.
  • NewAmsterdam Pharma Co N.V. annual Share-based Payment Arrangement, Expense for 2024 was $33,619,000, a 37% increase from 2023.
  • NewAmsterdam Pharma Co N.V. annual Share-based Payment Arrangement, Expense for 2023 was $24,572,000, a 488% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NewAmsterdam Pharma Co N.V. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $59,425,000 $14,023,000 +$4,608,000 +49% 01 Oct 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
Q3 2025 $54,817,000 $15,010,000 +$7,014,000 +88% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $47,803,000 $15,179,000 +$6,889,000 +83% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $40,914,000 $15,213,000 +$7,295,000 +92% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $33,619,000 $9,415,000 +$3,409,000 +57% 01 Oct 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
Q3 2024 $30,210,000 $7,996,000 +$2,604,000 +48% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $27,606,000 $8,290,000 +$2,732,000 +49% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $24,874,000 $7,918,000 +$302,000 +4% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $24,572,000 $6,006,000 01 Oct 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
Q3 2023 $5,392,000 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $5,558,000 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $7,616,000 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1

NewAmsterdam Pharma Co N.V. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $59,425,000 +$25,806,000 +77% 01 Jan 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
2024 $33,619,000 +$9,047,000 +37% 01 Jan 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
2023 $24,572,000 +$20,394,000 +488% 01 Jan 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
2022 $4,178,000 +$2,966,000 +245% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $1,212,000 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.